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Abstract
 .MA104 cells a monkey kidney cell line can internalize 5-methyltetrahydrofolate via a receptor mediated process termed
potocytosis. Uptake is initiated by binding to an external folate receptor which cycles to an internal, but membrane bound
w3 xcompartment. These two pools can be measured by determining the amount of H ligand removed by an acid-saline wash,
i.e. acid labile and acid resistant pools. When assayed in confluent nonmitotic cells, 2r3 of the folate receptor pool is
 .  .located in an internal acid resistant compartment, but phorbol 12-myristate 13-acetate PMA causes a shift such that
65–75% of the receptor pool resides on the surface of the plasma membrane. This new steady state is likely the result of an
w3 xincreased rate of receptor movement. In addition, PMA increases the rate of 5-methyl H tetrahydrofolate delivery to the
cytoplasm 1.8 fold. Using known inhibitors of potocytosis, we were able to show that the increased rate of delivery is
receptor mediated. Comparison of the time courses of the PMA effects on folate receptor redistribution assessed by
w3 x w3 xmembrane binding of H folic acid and 5-methyl H tetrahydrofolate delivery to the cytoplasm suggests that PMA may be
activating more than one protein kinase C independent signal transduction pathway. PMA is the first reported positive
modulator of receptor mediated folate uptake. q 1998 Elsevier Science B.V.
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1. Introduction
Folate is an essential vitamin which is utilized by
cells as a cofactor in purine and thymidine synthesis
as well as the metabolism of methionine, homo-
)  .Corresponding author. Fax: q1 214 648-3122; E-mail:
bkamen@mednet.swmed.edu
cysteine and serine. A folate deficiency, caused either
by malnutrition or antifolate therapy, results in a
megaloblastic anemia and may lead to increased risks
 w x.for cognitive disorders reviewed in 1 or cancer by
w xcausing uracil misincorporation in DNA 2 . There
are two known mechanisms for folate delivery from
the extracellular space to the cytoplasm: a carrier
mediated or a receptor initiated process. The reduced
0167-4889r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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 .folate carrier has a low affinity K s1–5mM ford
 .5-methyltetrahydrofolate 5CH THF , the predomi-3
nant form of folate found in human plasma 10–
.20 nM . Despite this relatively low concentration of
plasma 5CH THF, delivery is sufficient for most3
cells to thrive. For example, phytohaemaglutinin
stimulated lymphocytes, which are receptor negative,
6 w xaccumulate 40 fmol 5CH THFrhr10 cells 3 . Since3
lymphocytes have f600 fmol of 5CH THFr1063
cells, the cells can be ‘replenished’ in only 15 h even
if they initially had no folate. The cDNA for the
putative reduced folate carrier, RFC1, has been cloned
w xfrom mouse and hamster cells 4,5 . Based on the
murine RFC1 cDNA sequence, a human homolog
w xwas also isolated 6–8 . Transfection of RFC1 cDNA
into methotrexate resistant cells restores methotrexate
w xsensitivity 4,5,7,9 .
The second mechanism for folate transport, a re-
ceptor mediated process, is initiated via binding of
 .ligand to a glycosyl-phosphatidylinositol GPI an-
chored protein which has a much greater affinity than
the reduced folate carrier for both reduced and oxi-
 .dized folates K f1 and -0.1 nM respectivelyd
 w x.reviewed in 10 . The process of folate delivery by
the folate receptor is known as potocytosis reviewed
w x.in 11 . Based upon the kinetics of folate uptake and
metabolism, several steps have been postulated Fig.
.1 . First, folate binds to the receptor followed by
invagination of the plasma membrane. This ‘closed’
compartment is then acidified by a Hq pump which
reduces the affinity of folate for its receptor causing
it to dissociate. The vitamin is then transported into
the cell via a probenecid sensitive channel that may
be the reduced folate carrier. The receptors are then
exposed at the cell surface to repeat the cycle. Each
of these steps can be inhibited by various compounds
 . w xFig. 1 12–17 . However, no compounds have yet
been found to increase the rate of receptor mediated
folate delivery.
This model for receptor mediated folate uptake
w3 xwas based upon kinetics of H folic acid binding and
w3 x5CH H THF uptake and polyglutamation in a near3
confluent culture of MA104 cells, a monkey kidney
w xcell line 14,15,17,18 . Since the receptor is localized
w xin proximal tubule cells in the kidney 19 and is
present in renal cell carcinoma but not Wilm’s tumor,
w xthe latter being an embryonic kidney tumor 20,21 ,
we and others have suggested that the role of the
receptor is to prevent loss of folate in urine filtrate
w x22,23 . This implies that the receptor may have its
greatest impact in post-mitotic, differentiated cells
where its function is to facilitate specific organ or
tissue delivery or uptake of the vitamin, a notion
further supported by noting that folate receptor is also
expressed in the epithelium of the choroid plexus and
w xthe syncytiotrophoblastic cells in the placenta 19 .
Studies of folate receptor and folate accumulation in
stationary and exponentially growing MA104 cells in
w xvitro continue to support this theory 24 . Exponen-
tially growing MA104 cells have four fold less folate
receptor than mature MA104 cells and accumulate
folate primarily by a receptor independent process at
a rate almost two times greater than confluent cells
w x24 . However as MA104 cells mature, folate accu-
 .Fig. 1. Model of potocytosis: step 1- folate double ringed structure binds to folate receptors; step 2- membrane invagination; step 3-
acidification; step 4- folate delivery to cytoplasm; step 5- receptors return to surface of the plasma membrane. Compoundsrconditions
listed beneath model inhibit that step.
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mulation is primarily via a receptor dependent mech-
anism.
In order to more completely understand the func-
tion and regulation of the folate receptor in MA104
cells, we have been searching for compounds such as
hormones or drugs that affect receptor function. Here
we report the effects of phorbol 12-myristate 13-
 .acetate PMA on folate receptor location and cycling
and 5-methyltetrahydrofolate uptake in confluent
cells. We found that PMA causes a redistribution of
the folate receptor to a predominantly external locale,
increases the rate of folate receptor movement be-
tween the acid resistant and acid labile compartments
and increases the rate of cytoplasmic 5-methyltetra-
hydrofolate accumulation.
2. Materials and methods
2.1. Materials
RPMI 1640 medium without folic acid was pur-
chased from Gibco, Life Technologies Grand Island,
.NY , fetal bovine serum from Atlanta Biologicals
 . Norcross, GA and T25 flasks from Costar Cam-
.bridge, MA . PMA, 4-aPMA, chelerythrine chloride,
bisindolylmaleimide VIII, calphostin C, staurospo-
rine, and H-7 were purchased from Alexis Biochemi-
 .cals San Diego, CA . All other PKC inhibitors were
available through our pharmacy. Monensin was pur-
 .chased from Calbiochem San Diego, CA and Opti-
fluor scintillation fluid from Packard Instrument
 . w X X 3 xCompany Meriden, CT . 3 ,5 ,7,9- H folic acid, di-
 . w X Xammonium salt 10–30 Cirmmol, and 6S - 3 ,5 ,7,9-
3 xH 5-methyltetrahydrofolic acid 10–30 Cirmmol
were obtained from Moravek Biochemicals Brea,
.CA . Folic acid polyglutamate standards were synthe-
sized by Dr. G. Nair, University of South Alabama.
 .Folic acid FA , DL-5-methyltetrahydrofolic acid,
probenecid, trypsin, Hanks balanced salt solution
 .without phenol red HBBS , penicillinrstreptomycin
solution and all other reagents not stated were bought
 .from Sigma St. Louis, MO .
2.2. Methods
2.2.1. Tissue culture cells
MA104, a monkey kidney cell line, was purchased
from Whittaker M.A. Bioproducts and grown in folic
acid free RPMI supplemented with 20 nM DL-
5CH THF, 5% fetal bovine serum, 100 Urml of3
penicillin and 0.1 mgrml of streptomycin at 378C
under 5% CO in humidified air. MA104 cells were2
plated at 200 000 cells per T25 flask on day 0, fed on
day 4, and experiments performed on day 8. The cells
plated for experiments were not supplemented with
20 nM 5CH THF. The average cell number on day 83
ranged from 2.5–4 million MA104 cells per T25
flask.
[3 ]2.2.2. H FA binding assay
Cells were washed once with phosphate buffered
2q 2q  .saline without Ca and Mg PBS followed by
the addition of HBSS"1 mM PMA and incubated as
w3 x  .indicated at 378C; H FA 5 nM was then added.
For each set, an additional flask containing 500 nM
folic acid was also included in order to determine the
w3 xH -products that bound to the cell nonspecifically.
After the appropriate incubation time, the cells were
w xprocessed as previously described 24 . Briefly, the
cells were chilled, rinsed twice with PBS and washed
Fig. 2. Timecourse of folate receptor redistribution caused by
w3 xPMA: day 8 MA104 cells were incubated with 5 nM H FA for
3 h at 378C to saturate the receptor then 1mM PMA was added to
 .  .one set = at time zero. The acid labile AL and acid resistant
 .AR components were determined at each time point. The AL to
 .AR ratio was then calculated. Control cells ’ were not treated
 .with PMA, and pre-PMA cells v were pretreated with 1mM
w3 xPMA for 30 min before the addition of H FA.
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w3 xFig. 3. Timecourse of folate receptor saturation with H FA in the presence or absence of PMA: day 8 MA104 cells were incubated
 .  .  . w3 xwithout I or with 1 mM PMA for 30 , or 90 n minutes prior to the addition of 5 nM H FA. At each time point the cells were
rinsed with PBS and then dissolved with 0.2 N NaOH. Total radioactivity was determined by scintillation counting.
briefly with acid saline. This acid wash and following
 .rinse were used to determine the acid labile AL
 .fraction. The acid resistant AR fraction was deter-
mined by dissolving the cells in 0.2 N NaOH.
Initial experiments using PMA at concentrations
from 10y9 to 10y5 M confirmed a maximum effect
y6 w xby 10 M 25 . Therefore, we used 1 mM PMA in
all experiments unless otherwise stated. When the
time course of PMA activation was tested e.g. Fig.
. w3 x2 , the cells were incubated with H FA for 3 h
before the addition of PMA. When total FA binding
 .was determined e.g. Fig. 3 , the cells were washed
w3 xtwice with PBS after the H FA incubation and then
NaOH was added immediately, i.e. the acid saline
step was omitted.
[3 ]2.2.3. 5-Methyl H tetrahydrofolate uptake
The cells were washed once with PBS followed by
the addition of HBSS"1 mM PMA and incubated
30 min at 378C unless otherwise specified. The cells
w3 xwere then incubated with 20 nM 5-methyl H tetrahy-
drofolate. Nonspecific flasks included 6.6 mM
5CH THF. After the appropriate incubation time, the3
w xcells were processed as previously described 24
with only minor changes. Briefly, the cells were
w chilled, rinsed, and then buffer A 10 mM Tris pH
.8.0 , 1% b-mercaptoethanol, and 50 nM 5-methylte-
xtrahydrofolate was added to each flask and placed at
y708C for storage until needed. The flasks were
thawed on ice and the cell monolayers were scraped,
rinsed, and spun at 100 000=g. A portion of the
cytosol was counted to determine total uptake. The
pellet was dissolved in 0.1 N NaOH and the T25 flask
was rinsed with 0.1 N NaOH and added to the pellet
to determine total membrane binding. Folylpolygluta-
mates were separated on a reverse phase C18 column
w xusing a 40% acetonitrile gradient 15 . Several flasks
from each experiment were trypsinized and counted
on a hemocytometer to establish cell number.
[3 ]2.2.4. Potocytosis inhibitors: 5-methyl H tetrahydro-
folate assay
Cells were washed once with PBS followed by a
3 h incubation with HBSS"10 nM FA. 1 mM PMA,
10 mM probenecid, or 25mM monensin were then
added to the appropriate flasks and the cells were
incubated 30 min longer before 20 nM 5-
w3 xmethyl H tetrahydrofolate was added. Nonspecific
binding samples included 6.6 mM 5-methyltetrahy-
drofolate. The cells were incubated for 90 min at
378C before being processed for cytosol and mem-
brane fractions as described above.
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2.2.5. Kinase inhibitor FA binding assay
The cells were washed once with PBS followed by
w3 xa 2.5 h incubation with 5 nM H FA. Kinase in-
hibitors were then added and the incubation contin-
ued for an additional 30 min before the addition of
1 mM PMA. Two hours later, AL and AR were
determined as described above. When calphostin C
was tested, the first 20 min of the kinase inhibitor
incubation was at room temperature under ordinary
fluorescent illumination.
2.2.6. Kinase inhibitor 5-CH THF deli˝ery assay3
Cells were washed once with PBS and incubated
in HBSS"kinase inhibitors for 30 min at 378C fol-
lowed by an additional 1 h incubation with 1 mM
w3 xPMA and 20 nM 5-methyl H tetrahydrofolate before
being processed for cytosol and membrane fractions
as described above.
The data in the figures are from representative
experiments each of which was repeated at least three
times in duplicate. Each value shown is the average
of two duplicate flasks dpmsrduplicate flasks typi-
.cally varied by less than 10% with the nonspecific
control already subtracted unless stated differently.
Nonspecific controls for folic acid binding were f
3–4% of total counts bound. Nonspecific uptake of
5CH THF was generally 10–12% of the specific3
uptake. When radioactivity taken up by the cell was
analyzed by HPLC, )90% of the tritium co-chro-
matographed with known folate standards.
3. Results
3.1. PMA treatment results in ‘externalization’ of the
folate receptor
 .In near confluent MA104 cells day 5 , treatment
with PMA a drug commonly used to activate protein
.kinase C by acting as a diacylglycerol analog has
been shown to cause the majority of folate receptors
originally located in an internal compartment of the
w xcell to relocate to the cell surface 25 . We therefore
examined the effect of PMA on post confluent day 8
MA104 cells. In contrast to near confluent cells
 .which have a 1:1 ratio of ‘‘external’’ AL to ‘‘inter-
 .nal’’ AR folate receptors, cells in mature cultures
have 2r3 of the receptors in an internal compartment
 .i.e. ALrAR ratio of 0.5 . After treatment with PMA,
approximately 70% of the receptors reside in the
external, i.e. the AL compartment. The time course of
this change is shown in Fig. 2. After an initial lag of
approximately 30 min, there was a significant redistri-
bution of receptor from an AR“AL pool that oc-
curred over the next hour. Complete redistribution of
the receptor was reached by 90 min and sustained for
 .  .as long as has been tested 4.5 h data not shown . A
similar 30 min lag was seen when PMA and folic
acid were added simultaneously to day 8 MA104
 .cells as detailed below e.g. Fig. 6 .
[3 ]3.2. The saturation of folate receptor with H FA is
faster in the presence of PMA, but total binding
remains constant
w3 xSince the binding of H FA by the folate receptor
 y1is rapid 2.5% s in a cell free system at nanomolar
. w xconcentrations 13 , the folate receptors located in
 .the acid labile fraction surface should be saturated
within minutes. Therefore, it would be predicted that
the rate limiting factor for total folate receptor satura-
w3 xtion by H FA would be receptor movement from
the AR“AL compartment. As shown in Fig. 3,
although total membrane binding was equivalent in
 .control and PMA treated cells 3 h time point , it
appears that receptor movement from the AR“AL
compartment was faster in PMA treated cells, be-
cause saturation occurred much more quickly than in
control cells. In fact, the rate of folate receptor
saturation was faster in cells pretreated with PMA for
90 min compared to only 30 min. More rapid receptor
saturation was also seen if PMA was added simulta-
w3 x  .neously with H FA data not shown .
[3 ]3.3. Cytoplasmic deli˝ery of 5-methyl H tetrahydro-
folate is more rapid in PMA treated cells
Folic acid is a useful probe for receptor movement
 12 y1.because it has such a large affinity K f10 Ma
w x13 for the receptor compared to the natural ligand
 9 y1. w x5CH THF K f10 M 26 that it is not effi-3 a
ciently delivered to the cytoplasm when tested at
w xphysiological concentrations 14 and thus acts as a
marker for the receptor. To determine if PMA not
only affects receptor distribution, but also delivery of
w3 xfolate, cytoplasmic accumulation of 5-methyl H te-
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 .Fig. 4. Rate of 5-methyltetrahydrofolate accumulation is faster in PMA treated cells. Day 8 MA104 cells were incubated with ’ or
 . w3 xwithout B 1 mM PMA for 30 min prior to the addition of 20 nM 5-methyl H tetrahydrofolate. The cells were harvested at the indicated
 .times and the amount of cytoplasmic 5CH THF was determined as described in Section 2 panel A . Dotted lines indicate linear3
regressions through the first 2 h of folate delivery for each condition. The amount of folylpolyglutamates were determined by HPLC as
 .described in Section 2 panel B .
trahydrofolate was measured under control and PMA
 .stimulated conditions. As shown in Fig. 4 A , the
w3 xinitial rate of 5-methyl H tetrahydrofolate delivery
 .was 1.8"0.4 ns4 times faster in PMA treated
cells compared to non-treated MA104 cells. How-
ever, after 13 h, the amount of internalized folate was
equal. Therefore, PMA not only altered the ALrAR
ratio and increased the rate of receptor movement, it
also increased the rate of folate delivery to the cyto-
plasm, but not the total amount of folate accumu-
lated.
Shortly after 5CH THF enters the cytoplasm, it is3
often processed into a folylpolyglutamate by the en-
 .zyme folylpolyglutamate synthetase FPGS . This
modification increases the retention of the vitamin
inside the cell and its affinity for the enzymes that
w xuse it as a cofactor 27 . The percentages of
folylpolyglutamate species folylpentaglutamate and
.folylheptaglutamate detected by high pressure liquid
chromatography were indistinguishable between cy-
tosols tested from control and PMA stimulated cells.
w3 xHowever, since 5-methyl H tetrahydrofolate uptake
was increased by PMA, the amount of folylpolygluta-
mates synthesized was considerably larger in PMA
treated cells, especially at the early time points Fig.
 ..4 B .
[3 ]3.4. Methyl H tetrahydrofolate deli˝ery is receptor
mediated in PMA treated cells
We previously have shown that as MA104 cells
mature, the process by which they internalize folate
shifts from primarily a receptor independent, carrier
mediated process to a potocyticrreceptor mediated
event, and the rate of folate delivery is almost halved
w x24 . Therefore, it was important to determine if
mature MA104 cells treated with PMA were revert-
ing to a receptor independent pathway of folate deliv-
ery. There are many compounds that can differentiate
 .between these two possibilities Fig. 1 . If mature
MA104 cells are preincubated with FA to block the
w3 xfolate receptor, 5-methyl H tetrahydrofolate accumu-
lation decreases nearly 80% in both the control and
 .PMA treated cells Fig. 5 . This provides evidence
that 5CH THF uptake is largely due to a receptor3
dependent process. Delivery was also significantly
inhibited by monensin, an ionophore which presum-
ably blocks the acidification of the closed compart-
w3 xment thereby inhibiting the release of 5-methyl H te-
w xtrahydrofolate from the folate receptor 14 , and by
probenecid, a compound known to block anion trans-
porters. Probenecid has been shown to block both
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Fig. 5. PMA-stimulated day 8 MA104 cells internalize folate via potocytosis. Day 8 MA104 cells were incubated with or without 10 nM
 .  .  .  .folic acid FA for 3 h followed by the addition of 1 mM PMA right panel andror 10 mM probenecid prob or 25mM monensin mon
w3 x  6 .for 30 min. Then cytoplasmic 5-methyl H tetrahydrofolate delivery pmolr10 cells was measured as described in Section 2 after a
 . 90 min incubation with 20 nM ligand. Percent Delivery shown above each bar s100= amount of folate delivered per conditionramount
.of folate delivered by ‘‘control’’ or ‘‘PMA treated’’ cells .
receptor independent and dependent folate transport
w x w3 x15,28 . Transport of 5-methyl H tetrahydrofolate
andror methotrexate by folate receptor negative cell
 .lines such as U373 and BT104 brain tumor lines
 .and L1210 murine leukemia is not effected by PMA
 .unpublished data Lewis, Smith and Kamen lending
further support that PMA accelerates 5CH THF de-3
livery via a receptor mediated process.
3.5. PMA accelerates 5CH THF deli˝ery e˝en before3
folate receptor redistribution is detected
Whether cells were incubated with PMA for 30 or
w3 x90 min before 5-methyl H tetrahydrofolate addition,
the same increased rate of folate delivery to the
cytoplasm was measured. Based on this initial obser-
vation, we investigated whether redistribution of the
 w3 xfolate receptor which is detected by H folic acid
.binding 30–90 min after PMA addition was neces-
sary for the increased rate of 5-methyltetrahydro-
 .folate delivery to the cytoplasm Fig. 6 . As expected
w3 xFig. 6. PMA increases the rate of 5-methyl H tetrahydrofolate
accumulation before a shift in receptor localization can be de-
tected. Day 8 MA104 cells were incubated simultaneously with
w3 x w3 xPMA and either 5 nM H FA or 20 nM 5-methyl H tetrahydro-
folate. Control had no PMA added. After the time indicated, the
w3 x .  . w3 xacid labile fraction H FA B or cytoplasmic 5-methyl H te-
 .trahydrofolate ’ was determined as described in previous
figures and text. The values shown are the ratio of the PMA
treated to Control cells.
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w3 xfrom Fig. 2, when PMA and H FA were added
simultaneously, no significant increase in the acid
labile folate receptor population was measured at
30 min. However by 20 min, the cytoplasmic content
w3 xof 5-methyl H tetrahydrofolate in cells co-incubated
with PMA was increased 50% over the control cells
and by 30 min, by 75%.
3.6. PMA effect may not be mediated by PKC
Under most circumstances, PMA binds to and then
activates members of the conventional and novel
protein kinase C enzyme families. Within the last
several years, two other proteins, n-chimaerin and the
C. elegans protein Unc-13, have been shown to
possess high affinity binding sites for phorbol esters
w xas well 29 . In order to determine if PMA was
 .binding to and activating a member s of the PKC
family, we screened a series of PKC inhibitors with
different degrees of kinase specificity and sites of
w xinhibitory action 30,34 . Cells were incubated with
inhibitors for 30 min before the addition of PMA.
After an additional 2 h incubation, folate receptor
 .distribution was measured Fig. 7 . As shown previ-
 .ously Figs. 2 and 6 , incubation with PMA results in
a redistribution of the receptor such that approxi-
mately 70% is in the acid labile fraction. Only 100 nM
staurosporine completely blocks the effect of PMA,
although 500 mM H-7 inhibits a significant amount of
receptor redistribution as well. These two inhibitors
are not very specific for PKC; they bind to the ATP
w xbinding site of many kinases 30,35 . Bisindolyl-
maleimides are analogs of staurosporine and have
been shown to be more potent inhibitors of PKC
w xcompared to other kinases 30 . Here bisindolyl-
maleimide VIII was less effective than staurosporine.
Chelerythrine also has more selectivity for PKC com-
w xpared to other kinases 30,46 ; however it did not
inhibit the folate receptor redistribution caused by
PMA. Finally calphostin C, a compound designed to
bind to the regulatory domain of PKC and competi-
tively inhibit PMA binding also had no inhibitory
w xeffects in our assay 30,46 . This experiment was also
 .done at lower PMA concentrations 0.25–0.35 mM
with no qualitative changes in the results. Moreover,
these inhibitors had no effect on folate receptor distri-
bution when added alone. Based on these data, we
believe activation of PKC by PMA is not responsible
for folate receptor redistribution.
Additional studies have suggested to us that stau-
rosporine may be inhibiting an event downstream of
the PMA target because staurosporine can be added
subsequent to maximal PMA activity and still reverse
the folate receptor redistribution back to control lev-
 .els data not shown . Other drugs such as forskolin
 . w xand Bt cAMP protein kinase A activators , KN-622
w x wand W7 CaM kinase II inhibitors , genistein general
x wtyrosine kinase inhibitor , wortmannin PI3 kinase
x w xinhibitor , and anisomycin SAP kinase activator were
screened to see if they would mimic or inhibit the
folate receptor redistribution caused by PMA in hopes
of identifying known signalling proteins that may be
involved in this pathway. None had any effect.
Therefore, we currently have no leads to the signal
transduction events that are causing this folate recep-
tor redistribution.
The effect of the inhibitors on PMA stimulated
5CH THF delivery were quite different from those3
 .seen on receptor redistribution Fig. 8 . Stelazine,
thorazine, H-7, and chelerythrine completely inhib-
ited the stimulatory effect of PMA. Staurosporine and
calphostin C could only partially inhibit this effect,
and bisindolylmaleimide VIII was completely inef-
 .fective. In the control s for this experiment, the PKC
inhibitors incubated with the cells in the absence of
PMA, revealed that only 50 mM chelethryine had any
 .inhibitory effect data not shown . Thus the inhibition
of the PMA effect seen with the other drugs seems to
be specific for the PMA mediated component, but not
for ‘‘basal’’ folate receptor function.
w3 xFig. 7. Effect of PKC inhibitors on PMA stimulated FR redistribution. Cells were treated with 5 nM H FA for 2.5 h followed by the
addition of PKC inhibitors 100 nM staurosporine, 500 mM H-7, 78 mM thorazine, 56 mM stelazine, 500 nM bisindolylmaleimide VIII,
.50 mM chelerythrine, or 750 nM calphostin C . Thirty minutes later, 1 mM PMA was added and the cells harvested for AL and AR 2 h
 .  .later. A shows total binding subdivided into AL and AR components, B shows ALrAR ratio. Triplicate specific plates were used for
each condition; error bars denote the SEM.
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Fig. 8. Effect of PKC inhibitors on PMA stimulated folate delivery. Cells were treated with PKC inhibitors same concentrations as
. w3 x w3 xdescribed in Fig. 7 for 30 min prior to the addition of 1 mM PMA and 20 nM 5-methyl H tetrahydrofolate. Cytoplasmic 5-methyl H te-
 6 .trahydrofolate delivery pmolr10 cells was measured as described in Section 2 after a 60 min incubation. Triplicate specific plates were
used for each condition; error bars denote the SEM.
4. Discussion
FRa , the only folate receptor isoform expressed in
MA104 cells, has a very limited tissue distribution
which includes the choroid plexus, kidney and pla-
centa and excludes liver, muscle, brain and lympho-
w xcytes 3,19,31 . It is also up-regulated in many malig-
w xnant cancers of epithelial origin 20 . In order to more
completely understand the function of FRa , we have
expanded our studies of folic acid binding and
5CH THF uptake originally done in near confluent3
MA104 cells to include exponential and stationary
phase MA104 cells. We previously reported that
w3 xH thymidine labeling and 5CH THF uptake rates3
were directly related, but were inversely related to
quantity of folate receptor, i.e. folate receptor is not
w xrequired during rapid growth 24 . Here we have
more completely studied folate receptor movement
and 5CH THF uptake in confluent non-mitotic cells3
and have identified the first activator of potocytosis.
We have shown that PMA significantly alters the
ALrAR ratio of folate receptors. Under normal con-
ditions, only 1r3 of the folate receptors are located
 .on the surface of the plasma membrane AL , and
2r3 of the receptors are in an internal acid-resistant
 .compartment AR , that is to say ALrAR is 0.5.
Incubation with PMA drastically altered the distribu-
tion of folate receptors so that f70% of the recep-
tors are now located on the surface of the plasma
 .membrane Fig. 2 . We are not able to directly
measure the AR“AL folate receptor movement rate
without perturbing the cells significantly by an acid
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 .wash or drastic temperature changes 4“378C . The
increased rate of folate receptor movement is likely
the reason that the total folate receptor pool in PMA
w3 xtreated cells is labeled faster with H FA compared
 .to control cells Fig. 3 . Moreover, receptor move-
ment from the AL to AR compartment measured
w3 x within the first 5 min of H FA addition to insure
.measurement of only unidirectional movement is
also accelerated approximately two fold in cells pre-
treated with PMA for 30 min.
In addition to increased receptor movement, an
increased rate of delivery and metabolism of 5-
w3 xmethyl H tetrahydrofolate was found. This uptake
was blocked by compounds known to inhibit various
steps in the potocytic process. PMA is the first
compound we have found that accelerated receptor
mediated delivery; all previous compounds that al-
 .tered the process were inhibitors Fig. 1 .
These results are in partial contradiction to the
recently reported effects of PMA on MA104 cells
w xcultured only for 5 days 25 . In these studies, PMA
caused the folate receptor to shift to the cell surface,
w3 xbut 5-methyl H tetrahydrofolate delivery to the cyto-
plasm was inhibited. We have not been able to
w3 xreproduce the inhibition of 5-methyl H tetrahydro-
folate uptake by day 5 MA104 cells grown under the
conditions described here or those described previ-
w xously 25 . In our hands, PMA does not affect deliv-
w3 xery of 5-methyl H tetrahydrofolate in day 5 cells but
it does externalize the vast majority of the receptor.
One possible explanation for the differences between
the response of day 5 and 8 cells to PMA may be the
maturation of the cells which results in as yet unde-
fined but different signal transduction pathways being
operative. Since increased 5CH THF delivery can be3
detected before any measurable redistribution of the
folate receptor, it seems likely that the redistribution
of the receptor is not prerequisite for the initial, more
rapid delivery of 5CH THF to the cytoplasm seen in3
these post confluent cells. Rather, it is more likely the
increased rate of folate receptor movement that in-
creases 5CH THF accumulation.3
We suspect that PKC is not mediating the effects
of PMA. A wide range of PKC inhibitors, varying in
their specificities to inhibit PMA binding or kinase
activation, did not block the effect of PMA on folate
 .receptor redistribution Fig. 7 . The only compounds
that inhibited the effect of PMA were 500 mM H-7
and 100 nM staurosporine. At this concentration of
 .H-7 5–50 times its IC50 value , we assume it is not
acting specifically as a PKC inhibitor. Other proteins
known to bind phorbol esters such as Unc-13 and
w xn-chimaerin 29,32,33 should have been inhibited by
calphostin C, which binds to the phorbol ester bind-
ing site on these proteins as well as the PKC family.
Even though staurosporine inhibited folate receptor
redistribution caused by PMA at predicted IC50
concentrations, staurosporine inhibits other seriner
threonine and tyrosine kinases such as protein kinase
A, cGMP dependent protein kinase, and myosin light
w xchain kinase at similar concentrations 30,34 . More
specific PKC inhibitor analogs of staurosporine exist
such as bisindolylmaleimide VIII; this compound
which is 10–100 times more specific for PKC than
w xPKA 35 did not inhibit the folate receptor redistri-
bution caused by PMA.
The inhibitory effect of chelethryine on folate
delivery even in the absence of PMA, but not recep-
tor distribution may be a more important lead with
respect to non-receptor initiated but carrier mediated
folate uptake because the recently cloned reduced
 .folate carrier RFC has several consensus PKC sites.
In this regard, it should be noted that Said and
colleagues did not see an inhibitory effect of some
PKC and PKA inhibitors on RFC mediated uptake in
intestinal cells but did note that a protein tyrosine
 .kinase inhibitor genistein inhibited folate uptake by
w xdecreasing the apparent V 46 . This molecule didmax
not block transport in MA104 cells. Additional stud-
ies are clearly needed to sort out the control mecha-
nisms operative for folate accumulation via either
pathways. Based upon comparing the effects of some
of these compounds on the same cells at different
stages of confluence as well as different cell types
e.g. hepatocytes, intestinal cells, kidney epithelial
.cells and murine leukemiarlymphoma cells it seems
reasonable to assume that different regulatory path-
ways most likely exist.
 .Other PKC agonists such as y indolactam V and
phorbol 12,13 dibutyrate were equally effective in
our system and the PKC inactive analogs 4a-PMA,
 . .q indolactam V and 4a-phorbol 12,13 dibutyrate
had no stimulatory effects in our system. Based upon
these stereospecific structureractivity results, we hy-
pothesize that PMA is binding and activating a novel
 .protein s that contains a domain similar to the dia-
( )C.M. Lewis et al.rBiochimica et Biophysica Acta 1401 1998 157–169168
cylglycerolrphorbol ester binding domain found in
the protein kinase C family.
Since the folate receptor may be a useful immuno-
logical target or means of targeting drug delivery
 w x.  .reviewed in 10 elucidating mechanisms means
for altering its function in normal and malignant cells
is important if there is to be an increased therapeutic
efficacy with regard to selective delivery of anti-
folates. The work here coupled with our previous
w x studies 21,24,36–38 and the work of others e.g.
w x.39,40 reminds us that it is important to study the
function and regulation of the folate receptor in mul-
tiple models, because receptor functionrmalfunction
and modulation seems dependent on both cell lineage
and cell density or state of differentiation. The effects
seen here may also be applicable to other GPI an-
chored proteins which appear to distribute into multi-
w xple compartments in the membrane 41–45 .
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